In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
H R Sagara WijeratneDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0002-8209-5626 Avery M RunnebohmDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0001-6798-6407 Monica P BarronDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0001-8841-6614 Ariana J HamptonDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.
Rudong LiDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0002-2389-1737 Sarah A Peck JusticeDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0002-0658-732X Sophia H LenceskiDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.
James D RooneyDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0009-0007-0773-5834 Whitney R Smith-KinnamanDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0003-1174-0920 Gina S ChangDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0009-0006-6215-1316 Emma H DoudDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0003-0049-0073 Jungsu KimStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0002-6931-8581 Stephane PelletierDepartment of Medical & Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0002-1127-0212 Yunlong LiuStark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0002-2699-626X Jonah Z VilseckDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0001-7076-8996 Amber L MosleyDepartment of Biochemistry, Molecular Biology, & Pharmacology, Indiana University School of Medicine, Indianapolis, IN 46202.ORCID 0000-0001-5822-2894 Funding
Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3MQuality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2MIndiana Medical Scientist/Engineer Training ProgramT32GM148382 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI Benjamin Gaston, Emily K Sims · 2023 to 2026
$3.9MTraining Grant on Alzheimer's Disease and ADRD at Indiana UniversityT32AG071444 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI GARY E. LANDRETH, Bruce T Lamb · 2021 to 2026
$2.8MTackling Multifaceted Drug Design Problems with Lambda Dynamics Based TechnologiesR35GM146888 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI JONAH VILSECK · 2022 to 2026
$1.9MThermal proteome profiling for analysis of protein sequence variants in human genetic diseaseR01NS121550 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOSLEY, AMBER L. · 2021 to 2025
$1.9MPediatric and Adult Translational Cancer Drug Discovery and Development Training Program (PACT-D3)T32CA272370 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI David W Clapp, Mark R. Kelley · 2023 to 2026
$569kProteomic and functional analysis of missense variants of APOE associated with Alzheimer disease riskF30AG079580 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI WIJERATNE, HR SAGARA · 2022 to 2025
$159kNCATS NIH HHS UL1 TR002529NCI NIH HHS P30 CA082709NCI NIH HHS T32 CA272370NIA NIH HHS F30 AG079580NIA NIH HHS T32 AG071444NIGMS NIH HHS R35 GM146888NIGMS NIH HHS T32 GM148382NINDS NIH HHS R01 NS121550
6 · The paper itselfAbstract
Pathogenic variants in EXOSC3, a noncatalytic subunit of the RNA exosome, cause pontocerebellar hypoplasia type 1B (PCH1B), yet substantial variability in disease severity is observed among individuals carrying different EXOSC3 alleles. The molecular mechanisms of RNA exosome dysfunction in individuals carrying EXOSC3 p.G191 variants remains unresolved. To address this, we generated CRISPR/Cas9-engineered human cell models harboring EXOSC3 p.G191 variants and performed integrated transcriptomic, proteomic, and computational structural analyses. EXOSC3 p.G191 variants produced extensive, allele- and dosage-dependent alterations in gene expression and splicing, with heterozygous variants causing broad but attenuated disruption relative to homozygous EXOSC3 G191D/G191D cells. All EXOSC3 G191 variants promoted increased skipping of exon 3 in EXOSC3 transcripts, generating a short isoform predicted to encode an unstable proteoform. Molecular dynamics and λ-dynamics simulations predicted substantial thermodynamic destabilization of all EXOSC3 G191 variant proteoforms, consistent with reduced protein abundance and thermal stability measured by global proteomics and PISA. At the protein complex level, EXOSC3 p.G191 variants were associated with coordinated decreases in all RNA exosome core subunits and the exonuclease EXOSC10, consistent with destabilization of RNA exosome assembly and orphan protein decay. In contrast, the catalytic exonuclease DIS3 and multiple independent RNA processing pathways were upregulated, indicating compensatory recalibration of RNA metabolism. Together, these findings link variant-induced alternative splicing, RNA exosome complex destabilization, and adaptive network responses to phenotypic variability in EXOSC3 p.G191-associated disease.
Identifiers
PMID41659589
PMCPMC12873867
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390